title: Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
abstract: BACKGROUND
  In a proportion of adults with steroid-resistant nephrotic syndrome (SRNS), intravenous cyclophosphamide therapy fails. Tacrolimus may be a promising alternative to cyclophosphamide for such patients.
  
  
  METHODS
  Prospective observational study.
  
  
  METHODS
  19 adults with SRNS (6 with minimal change nephropathy, 8 with focal segmental glomerulosclerosis [FSGS], and 5 with mesangioproliferative glomerulonephritis) that did not respond to intravenous cyclophosphamide therapy were studied from January 2003 to September 2006. Oral tacrolimus was administered (target trough levels, 5 to 10 ng/mL) for 24 weeks, then reduced doses were given (target trough level, 3 to 6 ng/mL) for another 24 weeks.
  
  
  METHODS
  Histopathologic types: minimal change nephropathy (n = 6), FSGS (n = 8), and mesangioproliferative glomerulonephritis (n = 5).
  
  
  RESULTS
  
  
  
  METHODS
  outcome variables included complete remission (decrease in daily proteinuria to protein < or = 0.3 g/d), partial remission (decrease in daily proteinuria to protein < 3.5 g/d but > 0.3 g/d), relapse (increase in daily proteinuria to protein > or = 3.5 g/d in patients who had partial or complete remission), change in kidney function, and tacrolimus dosing and serum levels.
  
  
  RESULTS
  17 patients completed at least 24 weeks of tacrolimus therapy. Complete remission was achieved in 11 patients (64.7%), and partial remission was achieved in 3 (17.6%). Complete or partial remission was achieved in 5 of 5 patients with minimal change nephropathy, 4 of 7 patients with FSGS, and 5 of 5 patients with mesangioproliferative glomerulonephritis. Primary resistance to tacrolimus was seen in 3 patients (17.6%), all with FSGS. Mean times to achieve partial and complete remission were 5.6 +/- 1.4 and 8.0 +/- 5.1 weeks, respectively. In patients who achieved complete or partial remission, 35.7% experienced relapse during follow-up (mean, 37.6 +/- 13.4 months). Two patients had doubling of serum creatinine levels, both with FSGS.
  
  
  CONCLUSIONS
  Observational study.
  
  
  CONCLUSIONS
  Tacrolimus rapidly and effectively induced remission of SRNS in Chinese adults with disease refractory to treatment with intravenous cyclophosphamide. Treatment may be less effective in patients with FSGS.
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
authors.forename: Xiayu
authors.initials: X
authors.lastname: Li
authors.forename: Heng
authors.initials: H
authors.lastname: Li
authors.forename: Huijuan
authors.initials: H
authors.lastname: Ye
authors.forename: Qun
authors.initials: Q
authors.lastname: Li
authors.forename: Xuelin
authors.initials: X
authors.lastname: He
authors.forename: Xiaohui
authors.initials: X
authors.lastname: Zhang
authors.forename: Yilun
authors.initials: Y
authors.lastname: Chen
authors.forename: Fei
authors.initials: F
authors.lastname: Han
authors.forename: Qiang
authors.initials: Q
authors.lastname: He
authors.forename: Huipin
authors.initials: H
authors.lastname: Wang
authors.forename: Jianghua
authors.initials: J
authors.lastname: Chen
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002681:China; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000502:physiology*; D015432:Glomerulonephritis, Membranoproliferative / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D005923:Glomerulosclerosis, Focal Segmental / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008297:Male; D009402:Nephrosis, Lipoid / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D009404:Nephrotic Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D012189:Retrospective Studies; D013256:Steroids / Q000008:administration & dosage / Q000627:therapeutic use*; D016559:Tacrolimus / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D013256:Steroids; D003520:Cyclophosphamide; D003404:Creatinine; D016559:Tacrolimus